Znanstveni rad - Izvorni znanstveni rad
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
Biochemia Medica, 30 (2020), 1; 74-82. https://doi.org/10.11613/BM.2020.010702

Margetić, Sandra; Ćelap, Ivana; Delić Brkljačić, Diana; Pavlović, Nikola; Šupraha Goreta, Sandra; Kobasić, Ivana; Lovrenčić-Huzjan, Arijana; Bašić Kes, Vanja

Citirajte ovaj rad

Margetić, S., Ćelap, I., Delić Brkljačić, D., Pavlović, N., Šupraha Goreta, S., Kobasić, I. ... Bašić Kes, V. (2020). Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochemia Medica, 30. (1), 74-82. doi: 10.11613/BM.2020.010702

Margetić, Sandra, et al. "Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations." Biochemia Medica, vol. 30, br. 1, 2020, str. 74-82. https://doi.org/10.11613/BM.2020.010702

Margetić, Sandra, Ivana Ćelap, Diana Delić Brkljačić, Nikola Pavlović, Sandra Šupraha Goreta, Ivana Kobasić, Arijana Lovrenčić Huzjan i Vanja Bašić Kes. "Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations." Biochemia Medica 30, br. 1 (2020): 74-82. https://doi.org/10.11613/BM.2020.010702

Margetić, S., et al. (2020) 'Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations', Biochemia Medica, 30(1), str. 74-82. doi: 10.11613/BM.2020.010702

Margetić S, Ćelap I, Delić Brkljačić D, Pavlović N, Šupraha Goreta S, Kobasić I, i sur.. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochemia Medica [Internet]. 2020. [pristupljeno 26.06.2022.];30(1):74-82. doi: 10.11613/BM.2020.010702

S. Margetić, et al., "Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations", Biochemia Medica, vol. 30, br. 1, str. 74-82, 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:163:734731. [Citirano: 26.06.2022.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.